Navigation Links
Dr. Richard Rosenbloom Resumes Services To The Quigley Corporation's Pharma Subsidiary

DOYLESTOWN, Pa., July 10 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY),, today announced that Dr. Richard Rosenbloom has resumed providing services to the Company's Quigley Pharma subsidiary. Dr. Rosenbloom had been temporarily suspended from the Company in late May, 2009.

Ted Karkus, Chairman and interim CEO of the Company, said, "We are pleased to have Dr. Rosenbloom again serving our Pharma subsidiary and helping in the development and evaluation of our new products. The Company has long acknowledged Dr. Rosenbloom's importance to the continued development of our Pharma product lines. The Company is continuing to look into the issues that resulted in Dr. Rosenbloom's prior suspension, and we are pleased to have this very talented and experienced individual back in his laboratory while these matters are under review."

Dr. Richard Rosenbloom joined the Company in 2000 as Executive Medical Director and Chairman of its Medical Advisory Board. In 2001, he helped establish Quigley Pharma with the goal of developing naturally derived compounds and botanical prescription drugs addressing therapeutic areas that have not been successfully covered by major pharmaceutical companies.

Dr. Rosenbloom has served as Director of Medical Affairs for Asta Medica Pharmaceuticals, directing international clinical drug trials in diabetes complications, pain and cancer, and as Medical Director of Biotrax Clinical Research, a contract research organization (CRO) in diabetes complications and rheumatoid arthritis.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. ( conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.


    Ted Karkus                    Media                    Investor Relations
    Chairman of the Board, CEO    Karen Pineman            Carl Hymans
    The Quigley Corporation       G.S. Schwartz & Co.      G.S. Schwartz & Co.
    215.345.0919                  212.725.4500             212.725.4500

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Richard Greco Joins Mediware Board
2. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
3. Healthcare Veteran Richard Findlay Joins Diamond Management & Technology Consultants as Partner
4. Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission
5. Richard L. Antoine to Retire as P&Gs Global HR Officer
6. Reed Smith to Merge with Richards Butler Hong Kong
7. GSA confers 2007 Richard Kalish Innovative Publication Award to USCs Mather
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Richard Drouant Joins OrthoSynetics(TM) as Graphic Designer
10. Los Angeles Daily Journal Names Richardson & Patel Verdict Top in the State of California for 2007
11. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
Post Your Comments:
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad , ... added Chris Hafey and Claude Hooton to its board of directors. The announcement ... America (RSNA) 2015 Annual Meeting and continues to strategically transform its focus from ...
(Date:11/28/2015)... ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, ... With possible savings of up to 20% off orders $80 or more to free gifts ... every few hours. , As a competitive e-commerce website for skin care and cosmetic needs, ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... meeting in Washington D.C. revolved around the fact that proper dental care, both at-home ... stressed the link between periodontal disease (more commonly referred to as gum disease) and ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ... which demands kidney transplantation is expected to boost the market ... for organ transplantation. --> 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology: